Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Brandhagen, BreeAnn N ^a   Tieszen, Chelsea R ^a   Ulmer, Tara M ^a   Tracy, Maria S ^a   Goyeneche, Alicia A ^a   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; MIFEPRISTONE;

ACTIN FILAMENT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL ASSAY; CELL GROWTH; CELL SHAPE; CELL STRAIN LNCAP; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS; OVARY CANCER; PHASE CONTRAST MICROSCOPY; PROSTATE CANCER;

ACTIN CYTOSKELETON; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CYTOSTATIC AGENTS; FEMALE; HORMONE ANTAGONISTS; HUMANS; MALE; MIFEPRISTONE; NEOPLASM INVASIVENESS; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84872808227     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-35     Document Type: Article

References (62)

1. Fedele L, Berlanda N. Emerging drugs for endometriosis. Expert Opin Emerg Drugs 2004, 9(1):167-177.
2. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998, 178(6):1151-1156.
3. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003, 101(2):243-250.
4. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995, 64(1):187-190.
5. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004, 103(6):1331-1336.
6. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994, 80(3):527-534.
7. Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep 2009, 22(5):1237-1245.
8. Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment: are we ready?. Endocr Relat Cancer 2012, 19(3):R35-R50.
9. Heikinheimo O, Hsiu JG, Gordon K, Kim S, Williams RF, Gibbons WE, Hodgen GD. Endometrial effects of RU486 in primates-antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J Steroid Biochem Mol Biol 1996, 59(2):179-190.
10. Narvekar N, Cameron S, Critchley HO, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004, 89(5):2491-2497.
11. Schneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig 1998, 5(6):334-338.
12. Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res 2009, 29(4):1047-1052.
13. Rose FV, Barnea ER. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 1996, 12(5):999-1003.
14. Goyeneche AA, Seidel EE, Telleria CM. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs 2012, 30(3):967-980.
15. Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 2009, 34(3):743-755.
16. Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int 2009, 9:4.
17. Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007, 13(11):3370-3379.
18. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K, Du YH. Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo. World J Gastroenterol 2004, 10(12):1726-1729.
19. El Etreby MF, Liang Y, Johnson MH, Lewis RW. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 2000, 42(2):99-106.
20. El Etreby MF, Liang Y, Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 2000, 43(1):31-42.
21. Check JH, Sansoucie L, Chern J, Amadi N, Katz Y. Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res 2009, 29(8):2977-2980.
22. Check JH, Sansoucie L, Chern J, Dix E. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res 2010, 30(1):119-122.
23. Check JH, Dix E, Cohen R, Check D, Wilson C. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res 2010, 30(2):623-628.
24. Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res 1998, 94:231-254.
25. Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer 2012, 12:200.
26. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 2011, 11:207.
27. Broussard JA, Webb DJ, Kaverina I. Asymmetric focal adhesion disassembly in motile cells. Curr Opin Cell Biol 2008, 20(1):85-90.
28. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147(2):275-292.
29. Pernicova Z, Slabakova E, Kharaishvili G, Bouchal J, Kral M, Kunicka Z, Machala M, Kozubik A, Soucek K. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Neoplasia 2011, 13(6):526-536.
30. Waterman-Storer CM, Salmon WC, Salmon ED. Feedback interactions between cell-cell adherens junctions and cytoskeletal dynamics in newt lung epithelial cells. Mol Biol Cell 2000, 11(7):2471-2483.
31. Watanabe T, Noritake J, Kaibuchi K. Regulation of microtubules in cell migration. Trends Cell Biol 2005, 15(2):76-83.
32. Chhabra ES, Higgs HN. The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol 2007, 9(10):1110-1121.
33. Borm B, Requardt RP, Herzog V, Kirfel G. Membrane ruffles in cell migration: indicators of inefficient lamellipodia adhesion and compartments of actin filament reorganization. Exp Cell Res 2005, 302(1):83-95.
34. Rauch M, Loosfelt H, Philibert D, Milgrom E. Mechanism of action of an antiprogesterone, RU486, in the rabbit endometrium. Effects of RU486 on the progesterone receptor and on the expression of the uteroglobin gene. Eur J Biochem 1985, 148(2):213-218.
35. Moguilewsky M, Philibert D. RU 38486: potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J Steroid Biochem 1984, 20(1):271-276.
36. Yudt MR, Jewell CM, Bienstock RJ, Cidlowski JA. Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol 2003, 23(12):4319-4330.
37. Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA. Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol Cell Biol 2007, 27(6):2266-2282.
38. Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP. Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun 2009, 381(4):671-675.
39. Telleria CM, Goyeneche AA. Antiprogestins in ovarian cancer. Ovarian Cancer - Clinical and Therapeutic Perspectives 2012, 207-230. Rijeka, Croatia: Intech, Farghaly S.
40. Ewald J, Desotelle J, Almassi N, Jarrard D. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 2008, 98(7):1244-1249.
41. Kawakami Y, Hama S, Hiura M, Nogawa T, Chiba T, Yokoyama T, Takashima S, Tajiri H, Eguchi K, Nagai N, et al. Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res 2001, 21(4A):2537-2545.
42. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004, 23(6):1283-1290.
43. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 1998, 79(6):640-644.
44. Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, Robertson JF, Sutherland RL. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000, 6(7):2777-2787.
45. Musgrove EA, Lilischkis R, Cornish AL, Lee CS, Setlur V, Seshadri R, Sutherland RL. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer 1995, 63(4):584-591.
46. Lu S, Tsai SY, Tsai MJ. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 1999, 140(11):5054-5059.
47. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 1996, 93(24):13742-13747.
48. Hara E, Tsurui H, Shinozaki A, Nakada S, Oda K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem Biophys Res Commun 1991, 179(1):528-534.
49. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991, 196(1):33-39.
50. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003, 22(16):4212-4222.
51. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011, 11(7):503-511.
52. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, Van Der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436(7051):720-724.
53. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436(7051):725-730.
54. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109(3):335-346.
55. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004, 18(1):70-85.
56. Stricker J, Falzone T, Gardel ML. Mechanics of the F-actin cytoskeleton. J Biomech 2010, 43(1):9-14.
57. DeMali KA, Burridge K. Coupling membrane protrusion and cell adhesion. J Cell Sci 2003, 116(Pt 12):2389-2397.
58. Bershadsky AD, Balaban NQ, Geiger B. Adhesion-dependent cell mechanosensitivity. Annu Rev Cell Dev Biol 2003, 19:677-695.
59. Sen S, Kumar S. Cell-matrix De-adhesion dynamics reflect contractile mechanics. Cell Mol Bioeng 2009, 2(2):218-230.
60. Mammoto A, Huang S, Moore K, Oh P, Ingber DE. Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-kip1 pathway and the G1/S transition. J Biol Chem 2004, 279(25):26323-26330.
61. Mammoto A, Ingber DE. Cytoskeletal control of growth and cell fate switching. Curr Opin Cell Biol 2009, 21(6):864-870.
62. Assoian RK, Klein EA. Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol 2008, 18(7):347-352.